The San Francisco Firefighters Cancer Prevention Foundation provided the @GalleriTest to 1,450+ firefighters & EMTs. Multi-cancer early detection screening can be critical for those at elevated cancer risk. See Important Safety Information: bit.ly/3QHmPWo

Join our CMO, Jeffrey Venstrom, MD, and other leaders in #oncology at #HLTH2022 as they discuss how collaboration across the cancer community is contributing to closing the gap in health disparities: bit.ly/3W2bx31 @HLTHEVENT

On the episode 1 of #TheCancerSignal podcast, we discuss how multi-cancer early detection tests may improve cancer screening and #DetectCancerEarly, when treatment is more likely to be successful. Subscribe: bit.ly/3V1vWEL

GRAIL CEO Bob Ragusa said that through this partnership with John Hancock, "we can help change the status quo and continue in our goal to dramatically increase cancer detection from screening in the population to improve public health."

The results from the PATHFINDER data give us a glimpse into what the future of cancer screening will be. Dr. Eric Klein reflects on what makes MCED tests a game changer for cancer care. bit.ly/3RRKFzU #ESMO22

Following the PATHFINDER presentation at #ESMO22, our Chief Medical Officer, Jeffrey Venstrom, MD, shares what this data could mean for the future of multi-cancer early detection. #MCED #DetectCancerEarly bit.ly/3RRKFzU

Good morning from #ESMO22! Make plans to join us this Sunday as we present final data from the PATHFINDER study of our multi-cancer early detection @GalleriTest.

This weekend at #ESMO22 we will present final data from the PATHFINDER study of our multi-cancer early detection (#MCED) @GalleriTest. Learn more: bit.ly/3BoJ6nJ #DetectCancerEarly

We are expanding the offering of the @GalleriTest in the Midwest with a new partnership with @FollowMercy, which will offer the test to patients through its hospitals, clinics and outpatient facilities aimed at early detection of cancer. Learn more: ow.ly/BrIH50JU09M

We announced today that Fountain Health Insurance will offer 100% coverage of @GalleriTest to members as part of its annual wellness benefits. Learn more: bit.ly/3bj80KX. #DetectCancerEarly

We presented the trial design for the largest-ever study of a multi-cancer early detection test at #ASCO22. The NHS-Galleri trial will enroll 140k volunteers to evaluate the potential of @GalleriTest to reduce later stage cancer diagnosis in the UK. bit.ly/3zprszL

We are proud to announce a new collaboration with @AstraZeneca to develop companion diagnostic tests and identify patients with high-risk, early-stage disease who could benefit from novel therapies. Learn more: bit.ly/3PQcwjT

Dr. Charles Atwood, pulmonologist and lead researcher for @VAPittsburgh, discusses the importance of #MCED testing for veterans and why he is participating in a real-world study evaluating the @GalleriTest. #ASCO22

We are partnering with @VAPittsburgh and @VeteransHealth to provide @GalleriTest to 10,000 veterans across 10 participating sites to help #DetectCancerEarly. Read more: bit.ly/38SxVZa

We’re excited to share that we won a MedTech Breakthrough Award! GRAIL was named Best Overall Medical Device Company by @MedTech_Awards. bit.ly/3vIoDr8 #MedTechBreakthroughAwards #DetectCancerEarly

We stand ready to accelerate the President’s Cancer Moonshot and believe MCED tests like @GalleriTest will help make it possible. Read our full statement: bit.ly/3GGSgLC

ICYMI: Listen to GRAIL President and Chief Medical Officer @DrJoshuaOfman on the @ReachMD podcast where he talks about all things @GalleriTest and MCED. #DetectCancerEarly reachmd.com/programs/medical…